Detection of Syndecan 2 (SDC2) methylation in stool DNA is a novel method for the auxiliary diagnosis of early colorectal cancer (CRC). Currently, this method has been widely applied; however, its accuracy and reliability have not been determined. The objective of this pioneering study was to evaluate the performance of clinical laboratories in China for their ability to detect SDC2 methylation from stool DNA.
We generated a sample panel consisting of clinical and cell samples. The clinical samples were stool specimens from patients with or without CRC, including four positives (prepared by serial dilution from one stool specimen), one negative and one interferential sample. Two cell samples, with positive or negative methylated SDC2, were used as controls. The panel was distributed to 32 clinical laboratories for analysis of SDC2 methylation, and the results were compared and scored.
The sample panel was compatible with commercially available assays and it showed appropriate stability to be an external quality assessment material. There were four false results; one hospital laboratory and one commercial diagnostic laboratory had a false-positive and a false-negative result, respectively, and one commercial diagnostic laboratory had both a false-positive and false-negative result. Among the 32 participating laboratories, 29 (90.62%) obtained an acceptable or better performance score, while 3 (9.38%) laboratories required improvement.
Our results demonstrate that the detection of SDC2 methylation from stool DNA was satisfactory in China. Additionally, the importance of external quality assessment was highlighted for monitoring the performance of clinical laboratories.
Funding source: Natural Science Foundation of Shanghai
Award Identifier / Grant number: (No. 21ZR1455900)
Funding source: Shanghai Municipal Health Commission
Award Identifier / Grant number: (No. 201940264)
Funding source: Shanghai Centre for Clinical Laboratory
Award Identifier / Grant number: (Nos. 2021ZXKT-01, 2021ZXKT-02)
Funding source: Youth Medical Talents-Clinical Laboratory Practitioner Program of Shanghai “Rising Stars of Medical Talents” Youth Development Program
Research funding: This study was supported by grants from Natural Science Foundation of Shanghai (No. 21ZR1455900), Shanghai Municipal Health Commission (No. 201940264), Shanghai Centre for Clinical Laboratory (Nos. 2021ZXKT-01, 2021ZXKT-02) and Youth Medical Talents-Clinical Laboratory Practitioner Program of Shanghai “Rising Stars of Medical Talents” Youth Development Program. The funding organizations played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the Ethical Committee of Shanghai Centre for Clinical Laboratory (202203).
1. Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca – Cancer J Clin 2021;71:209–49. https://doi.org/10.3322/caac.21660.Search in Google Scholar PubMed
3. Niu, F, Wen, J, Fu, X, Li, C, Zhao, R, Wu, S, et al.. Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2017;26:1411–9. https://doi.org/10.1158/1055-9965.epi-17-0153.Search in Google Scholar PubMed
4. Quintero, E, Castells, A, Bujanda, L, Cubiella, J, Salas, D, Lanas, A, et al.. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697–706. https://doi.org/10.1056/nejmoa1108895.Search in Google Scholar
5. Berger, BM, Ahlquist, DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathol 2012;44:80–8. https://doi.org/10.1097/pat.0b013e3283502fdf.Search in Google Scholar
6. Kadiyska, T, Nossikoff, A. Stool DNA methylation assays in colorectal cancer screening. World J Gastroenterol 2015;21:10057–61. https://doi.org/10.3748/wjg.v21.i35.10057.Search in Google Scholar PubMed PubMed Central
7. Vedeld, HM, Goel, A, Lind, GE. Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives. Semin Cancer Biol 2018;51:36–49. https://doi.org/10.1016/j.semcancer.2017.12.004.Search in Google Scholar PubMed PubMed Central
9. Wang, J, Liu, S, Wang, H, Zheng, L, Zhou, C, Li, G, et al.. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study. Clin Epigenet 2020;12:162. https://doi.org/10.1186/s13148-020-00954-x.Search in Google Scholar PubMed PubMed Central
10. Park, H, Kim, Y, Lim, Y, Han, I, Oh, ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002;277:29730–6. https://doi.org/10.1074/jbc.m202435200.Search in Google Scholar
11. Oh, TJ, Oh, HI, Seo, YY, Jeong, D, Kim, C, Kang, HW, et al.. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenet 2017;9:126. https://doi.org/10.1186/s13148-017-0426-3.Search in Google Scholar PubMed PubMed Central
12. Han, YD, Oh, TJ, Chung, TH, Jang, HW, Kim, YN, An, S, et al.. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenet 2019;11:51. https://doi.org/10.1186/s13148-019-0642-0.Search in Google Scholar PubMed PubMed Central
13. Glockner, SC, Dhir, M, Yi, JM, McGarvey, KE, Van Neste, L, Louwagie, J, et al.. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009;69:4691–9. https://doi.org/10.1158/0008-5472.can-08-0142.Search in Google Scholar PubMed PubMed Central
14. Wang, DR, Tang, D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008;14:524–31. https://doi.org/10.3748/wjg.14.524.Search in Google Scholar PubMed PubMed Central
15. Xie, L, Jiang, X, Li, Q, Sun, Z, Quan, W, Duan, Y, et al.. Diagnostic value of methylated septin9 for colorectal cancer detection. Front Oncol 2018;8:247. https://doi.org/10.3389/fonc.2018.00247.Search in Google Scholar PubMed PubMed Central
16. Kettelhut, MM, Chiodini, PL, Edwards, H, Moody, A. External quality assessment schemes raise standards: evidence from the UKNEQAS parasitology subschemes. J Clin Pathol 2003;56:927–32. https://doi.org/10.1136/jcp.56.12.927.Search in Google Scholar PubMed PubMed Central
17. Whitehead, SJ, French, J, Brookes, MJ, Ford, C, Gama, R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013;50:53–61. https://doi.org/10.1258/acb.2012.011272.Search in Google Scholar PubMed
18. O’Driscoll, S, Piggott, C, Bruce, H, Benton, SC. An evaluation of ten external quality assurance scheme (EQAS) materials for the faecal immunochemical test (FIT) for haemoglobin. Clin Chem Lab Med 2020;59:307–13. https://doi.org/10.1515/cclm-2020-0210.Search in Google Scholar PubMed
19. Greub, G, Sahli, R, Brouillet, R, Jaton, K. Ten years of R&D and full automation in molecular diagnosis. Future Microbiol 2016;11:403–25. https://doi.org/10.2217/fmb.15.152.Search in Google Scholar PubMed
20. Gulley, ML, Braziel, RM, Halling, KC, Hsi, ED, Kant, JA, Nikiforova, MN, et al.. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med 2007;131:852–63. https://doi.org/10.5858/2007-131-852-clrimp.Search in Google Scholar PubMed
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2022-0206).
© 2022 Walter de Gruyter GmbH, Berlin/Boston